The company plans to resume its CATT1 Phase 3 trial for type 1 diabetes after submitting a protocol amendment.
High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary endpoint with statistical ...
A revolutionary new drug trial called LION aims to ravage the ... a cancer immunologist from the Cancer Research UK Manchester Institute, University of Manchester. With plans to recruit 89 ...
Evidence has shown that 25% of patients with chronic lower back pain could be suffering from an infection in the disc space.
Merck KGaA’s oral TLR7/8 inhibitor enpatoran has failed to meet the primary endpoint in a subgroup of patients, but ...
The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...